Spinal and Bulbar Muscular Atrophy Clinical Trial
Official title:
Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy)
This study will determine if the drug dutasteride can improve weakness, mobility,
functioning, nerve function, and quality of life in patients with spinal and bulbar muscular
atrophy (SBMA). Patients with this inherited disease have an abnormal androgen receptor
protein. The male hormones testosterone and dihydrotestosterone (DHT) bind to this abnormal
receptor, causing damage to nerve cells that innervate muscle and leading to weakness.
Dutasteride decreases DHT production. Lowering DHT levels may decrease the harmful effects
of DHT to the nerves and improve strength in people with SBMA.
Males 18 years of age and older with SBMA who have neurological symptoms and can walk 100
feet (with or without assistive devices) may be eligible for this study. Candidates are
screened with a blood test and a review of their medical records and genetic studies.
Participants undergo the following procedures:
- Blood and urine tests, history and physical examination, assessment of muscle strength
- Quality-of-life questionnaire
- Tests to assess functional abilities, such walking up steps, keeping the head up while
lying down, and other measures
- Nerve conduction study and motor unit number estimation to assess nerve damage. A probe
placed on the skin delivers small electrical impulses and wires taped to the skin
record the impulses.
- Quantitative muscle testing to measure strength. The subject pushes and pulls levers
attached to a gauge. Strength is recorded by a computer.
- Medication. Participants are divided into two groups. One group is given the study
drug, dutasteride; the other receives a placebo (sugar pill). All participants take
their assigned medication once a day for 24 months.
- Follow-up evaluations. Every 6 months for 2 years, participants return to NIH to repeat
the tests described above to determine the effects of the dutasteride. Nerve and
quantitative muscle testing is not done at the 6- and 18-month visits.
- In addition to their follow-up appointments here at the NIH every 6 months,
participants will also have blood tests and a physical examination performed after 3,
9, 15 and 21 months of treatment by the patient's local physician.
Status | Completed |
Enrollment | 57 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Genetically confirmed SBMA - Neurological symptoms of SBMA - Ability to ambulate 100 feet with or without the use of assistive devices - Willingness to participate in all aspects of trial design and follow-up - Male sex Exclusion Criteria: - Age less than 18 years - Female sex - A history of hypersensitivity to dutasteride or 5 alpha-reductase inhibitors. - Exposure to 5 alpha-reductase inhibitors, anti-androgens, testosterone, or steroids in the preceding 6 months - Patients who are taking potent cytochrome P450 3A4 (CYP3A4) inhibitors for over 4 weeks - Patients with any pre-existing liver disease - Alkaline phosphatase, gamma glutamyl transferase, or direct bilirubin greater than 1.5 times the upper limit of normal - Alanine aminotransferase or aspartate aminotransferase greater than 1.5 times upper limit of normal in subjects with normal creatine kinase levels - Creatinine greater than 1.5 times the upper limit of normal - Platelet count, white blood cell count or hemoglobin below the lower limit of normal - Other clinically significant medical disease that, in the judgment of the investigators, would expose the patient to undue risk of harm or prevent the patient from completing the study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Fernández-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE, Levy EW, Solomon BI, Harris-Love MO, La Pean A, Schindler AB, Chen C, Di Prospero NA, Fischbeck KH. Efficacy and safety of dutasteride in patie — View Citation
Rhodes LE, Freeman BK, Auh S, Kokkinis AD, La Pean A, Chen C, Lehky TJ, Shrader JA, Levy EW, Harris-Love M, Di Prospero NA, Fischbeck KH. Clinical features of spinal and bulbar muscular atrophy. Brain. 2009 Dec;132(Pt 12):3242-51. doi: 10.1093/brain/awp25 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Muscle Strength Change From Baseline | Quantitative muscle assessment (QMA) was done with a fixed frame dynamometer, a strain gauge tensiometer, and a computer-aided acquisition system. Maximal voluntary isometric muscle contractions were measured twice, the average was calculated, and the results were summed over 22 muscle groups (11 on each side). The total force was scaled for body weight and expressed as percent change from baseline. Measurements were performed at 0, 12, and 24 months. The calculated percent changes at 12 and 24 months are shown. | 0, 12, and 24 months | No |
Secondary | Creatine Kinase, Change From Baseline | Serum creatine kinase was determined in venous blood samples analyzed at the Department of Laboratory Medicine of the NIH Clinical Center. | 0, 12, and 24 months | No |
Secondary | Manual Muscle Testing, Change From Baseline. | Manual muscle testing was performed using a modified Medical Research Council (MRC) scale (0=worst, 5=best); the average muscle score was based on 22 muscle groups. | 0, 12, and 24 months | No |
Secondary | Adult Myopathy Assessment Tool, Change From Baseline | The Adult Myopathy Assessment Tool rates physical function and muscle endurance, with higher scores indicating better performance; it includes 7 timed functional tasks and 6 endurance tasks (0=worst, 45=best). | 0, 12, and 24 months | No |
Secondary | Timed 2-minute Walk, Change From Baseline | The subjects did the 2-minute walk in a 50-foot (15.2-meter) corridor three times, and the average distance was calculated. The subjects were allowed to use an assistive device and rest between the trials. | 0, 12, and 24 months | No |
Secondary | Swallow Score Average, Change From Baseline | Modified barium swallow studies were done at 0, 12, and 24 months. Twenty-five domains were assessed, and six were chosen for final analysis based on the abnormal findings in subjects evaluated at baseline: vallecular pooling and repeated-swallow, each assessed with thin liquids, purees, and solids (rated 1-4, abnormal to normal). | 0, 12, and 24 months | No |
Secondary | Bulbar Rating Scale, Change From Baseline | The Bulbar Rating Scale includes eight domains each rated on a 1-4 scale, abnormal to normal. The original 8-32 point scale was transformed to a 0-100% scale to represent the responses as percentages. | 0, 12, and 24 months | No |
Secondary | Sensory Nerve Action Potential Average, Change From Baseline | Nerve conduction studies were done on four sensory nerves (median, ulnar, radial, sural), and the amplitudes of the evoked responses were averaged. Loss of amplitude indicates impairment of conduction. | 0, 12, and 24 months | No |
Secondary | Median Compound Muscle Action Potential, Change From Baseline | Nerve conduction studies were done on the median motor nerve, and the compound muscle action potential amplitude was determined. Loss of amplitude indicates impairment of conduction. | 0, 12, and 24 months | No |
Secondary | Peroneal Compound Muscle Action Potential, Change From Baseline | Nerve conduction studies were done on the peroneal nerve, and the compound muscle action potential amplitude was determined. Loss of amplitude indicates impairment of conduction. | 0, 12, and 24 months | No |
Secondary | Motor Unit Nerve Estimation, Change From Baseline | Motor unit number estimation (MUNE) was done with a statistical MUNE program, on the abductor pollicis brevis. All subjects were evaluated on the right side unless severe atrophy produced very low compound muscle action potentials; in this case, the left side was investigated or the abductor digiti minimi was substituted. A decrease in MUNE indicates a loss of motor units. | 0, 12, and 24 months | No |
Secondary | Activities of Daily Living, Change From Baseline | Subjects rated their daily activity with a modified 9-question Activities of Daily Living (ADL) questionnaire (0-4, fully impaired to normal). | 0, 12, and 24 months | No |
Secondary | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline | Subjects completed the Medical Outcomes Study Short Form Version 2 (SF-36v2), in which they rated their physical quality of life over the preceding 4 weeks. Raw SF-36v2 scores were converted to norm-based scales and component summaries using the scoring code provided by QualityMetric (mean=50, standard deviation (SD)=10). | 0, 12, and 24 months | No |
Secondary | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline | Subjects completed the Medical Outcomes Study Short Form Version 2 (SF-36v2), in which they rated their mental quality of life over the preceding 4 weeks. Raw SF-36v2 scores were converted to norm-based scales and component summaries using the scoring code provided by QualityMetric (mean=50, standard deviation (SD)=10), and percent change in the norm-based scale was calculated. | 0, 12, and 24 months | No |
Secondary | International Index for Erectile Function (IIEF), Change From Baseline | Sexual function was rated using the International Index of Erectile Function (IIEF). The total IIEF score (5-75, worst-best) was reported as the percent maximum (0-100%). | 0, 12, and 24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04944940 -
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
|
||
Recruiting |
NCT03555578 -
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
|
||
Recruiting |
NCT06411912 -
A Study of NIDO-361 in Patients With SBMA
|
Phase 2 | |
Completed |
NCT02156141 -
High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy
|
N/A | |
Completed |
NCT02024932 -
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
|
Phase 2 | |
Active, not recruiting |
NCT05517603 -
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06169046 -
A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy
|
Phase 2 |